Licensing Contact: J. Peter Kim, 301/496–7056 ext. 264

The invention provides compositions and methods directed to isolated α subunits of the 7TM protein CD97. CD97 is a heterodimer existing in three isoforms, namely three forms of α subunit and one invariant β subunit. The invention provides compositions and methods for detecting a subunit of CD97, a T-cell protein which is unregulated in activated T-cells and is involved in the onset and maintenance of inflammation and angiogenesis. The invention provides an isolated protein comprising a soluble CD97 α subunit, and an isolated nucleic acid encoding a soluble Cd97 α subunit protein. The invention also provides methods for identifying compounds which inhibit soluble CD97 α subunit expression. The invention may be used to inhibit angiogenesis associated with chronic inflammation in a mammal by administering a therapeutically effective amount of a CD97 antagonist. Another application includes determining the degree of inflammation at a site in a mammal with an antibody composition specifically reactive to a soluble CD97 α subunit. Further, it should be noted that these compositions and methods further have in vitro utility in the construction of proteins and subsequences thereof for the construction of antibodies, and nucleic acids and subsequences thereof for use as probes.

Peptides With Laminin Activity

Y Yamada, JO Graf, Y Iwamoto, F Robey, HK Kleinman,
M Sasaki, GR Martin (NIDR)
U.S. Patent 5,092,885 issued 03 Mar 92
Licensing Contact: Jaconda Wagner, 301/496–7735, ext. 284

Peptides with laminin activity, including YIGSR, are claimed. These peptides block angiogenesis, alter the formation of capillary structures by endothelial cells, prevent the formation of excess blood vessels in tissue and inhibit in vivo tumor cell colonization of tissues. These peptides can be used, among other things, to inhibit metastasis.

This research has been described in B.J. Cancer 73:589, 1996; Cancer Res 54:5005, 1994; Semin Cancer Biol 1993 Aug; 4(4):259–65; Cancer Res 1993 Aug 1;53(15):3459–61; Cell 1987 Mar 27;48(6):989–9.

Laminin A Peptides

Y Yamada, HK Kleiman, M Sasaki, GR Martin (NIDR)
U.S. Patent 5,211,657 issued 18 May 93
Licensing Contact: Jaconda Wagner, 301/496–7735, ext. 284

This invention relates to peptides and derivatives thereof having laminin-like activity, as well as a pharmaceutical composition of the peptide. The peptides claimed include Serine-Isoleucine-Lysine-Valine-Alanine-Valine (SIKVAV). Methods for promoting increased adhesion and migration of epithelial cells is also disclosed. The peptides have wide usage in research, nerve regeneration and cancer treatment. For example, this invention may be useful as an adhesion and regeneration agent for nerve guides and as an adhesion agent for vascular prothesis.

This research had been described in Bioorganic Medinal Chem Lett 5:711, 1995; J Neurosci Res 1995 Oct 15;42(3):314–22; Cancer Res 1995 Jun 1;55(11):2476–80; FEBS Lett 1995 May 29;365(2–3):227–3; J Cell Physiol 1994 Jul;160(1):185–93; Cell Immunol 1994 Jan; 153(1):94–104.

Dated: September 25, 1997.

Barbara M. McGarey,

Deputy Director, Office of Technology Transfer.

[FR Doc. 97–26171 Filed 10–1–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting of the National Cancer Institute Special Emphasis Panel (SEP) meeting:

Name of SEP: Efficacy Studies of Chemopreventive Agents in animal Models and Evaluation of Chemopreventive Agents by in Vivo Screening Assays.

Date: October 20–21, 1997.

Time: 8:30 a.m. to 5:00 p.m.

Place: Double Tree Hotel—Rockville, 1750 Rockville Pike, Rockville, MD 20852.

Contact Person: Courtney M. Kerwin, Ph.D., M.P.H., Scientific Review Administrator, National Cancer Institute, NIH, Executive Plaza North, Room 630I, 6130 Executive Boulevard, MSC 7405, Bethesda, MD 20892–7405, Telephone: 301/496–7421.

Purpose/Agenda To review and evaluate proposals submitted in response to master agreement announcements.

The meeting will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Numbers: 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control.)

Dated: September 26, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–26167 Filed 10–1–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Child Health and Human Development; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 United States Code Appendix 2), notice is hereby given of the following National Institute of Child Health and Human Development Special Emphasis Panel (SEP) meeting:

Name of SEP: Duration of Labor and Cesarean Delivery in Association With Epidural Analgesia in Nullipara (Teleconference).

Date: September 30, 1997.

Time: 11:00 a.m. (ET)—adjournment.

Place: 6100 Executive Boulevard, 6100 Building—Room 5E01, Rockville, Maryland 20852.

Contact Person: Hameed Khan, Ph.D., Scientific Review Administrator, NICHD, 6100 Executive Boulevard, 6100 Building—Room 5E01, Rockville, Maryland 20852, Telephone: 301–496–1696.

Purpose/Agenda: To provide concept review of proposed contract solicitations.

The meeting will be closed in accordance with the provisions set forth in secs. 552b(c)(9)(B), Title 5 U.S.C. The discussions could reveal the specific details of future requests for contract proposals (RFPs), the disclosure of which would significantly frustrate implementation of the agency's proposed contract activities by giving unfair competitive advantage to private firms or individuals.

This notice is published less than 15 days prior to the meeting due to the urgent need to meet timing limitations imposed by the review and funding cycle.

(Catalog of Federal Domestic Assistance Program Nos. [93.864, Population Research and No. 93.865, Research Mothers and Children], National Institutes of Health)

Dated: September 25, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–26099 Filed 10–1–97; 8:45 am]

BILLING CODE 4140–01–M